

## WELCOME

The EBMT Lymphoma Working Party Educational Course is a yearly 2-day meeting on transplant and cellular therapy for lymphoproliferative diseases.

The meeting starts with the Scientific Business Meeting, where all current and future studies are discussed. This is a unique opportunity for new or future members of the Working Party to get to know the activities and get involved in ongoing or future projects.

The core programme covers the most frequent types of lymphoma such as Hodgkin lymphoma, aggressive and indolent non Hodgkin lymphomas including mantle cell, peripheral T cell lymphoma and cutaneous T cell lymphoma. One of the sessions also focuses on supportive care in cellular therapy, and the last session covers innovation in allotransplant. Presentations are given by experts with a focus on educational and pedagogic value. Time will also be allocated to interactive case presentations. The programme is built to target a broad audience of trainees, nurses and early to mid-career practitioners interested in lymphoma and cellular therapy.

Yours sincerely,

Ali Bazarbachi — Lymphoma Working Party Chair

Charalampia Kyriakou — Lymphoma Working Party Secretary

Olivier Hermine — Lymphoma Working Party SPC Member and Local Organiser

Anna Sureda — EBMT President & Lymphoma Working Party SPC Member

## Wednesday, 5 November 2025

**14:30-18:00 Lymphoma Working Party Scientific Business Meeting**

## Thursday, 6 November 2025

**09:00-09:10 Welcome from the organizers**

Ali Bazarbachi (LB) & Olivier Hermine (FR)

**09:10-11:10 Session I: Aggressive lymphomas – DLBCL**

**Chair: Bertram Glass (DE) & Christian Gisselbrecht (FR)**

This session is kindly supported by Pierre Fabre, which has had no involvement in its selection, development, content or organization of the session

09:10-09:40 New classifiers: does it matter for treatment

Fabrice Jardin (FR)

09:40-09:50 Discussion

09:50-10:00 Clonal Evolution and Antigen Escape in Double-Hit DLBCL: An Aggressive Case with Early CAR-T Failure

Igor Kos (DE)

10:00-10:10 From CAR-T Failure to Allogeneic Transplant: Glofitamab-Enabled Remission in Relapsed DLBCL

Taner Tan (TR)

10:10-10:40 Critical discussion of the two cases (10') and CTL anti EBV (20')

Sylvain Choquet (FR)

10:40-11:10 Is there still a role for autologous SCT in DLBCL?

Christian Gisselbrecht (FR)

10:40-10:50 Yes

Bertram Glass (DE)

10:50-11:00 No

11:00-11:10 Discussion

**11:10-11:40 Coffee break**

**11:40-13:00 Session II: Mantle cell lymphoma**

**Chairs: Morgane Cheminant (FR) & Peter Dreger (DE)**

11:40-12:00 New classifiers: does it matter for treatment

Morgane Cheminant (FR)

12:00-12:10 Successful treatment with CAR T cells for Neurological and CSF Refractory Mantle cell lymphoma

Clémence Loiseau (FR)

12:10-12:30 Discussion of the non-cellular therapy strategics

Olivier Hermine (FR)

12:30-12:50 Discussion of the cellular therapy options: transplant, CART-T and bi-specifics

Peter Dreger (DE)

12:50-13:00 Discussion

**13:00-14:00 Lunch break**

**14:00-15:20 Session III: Indolent B cell lymphoma**

**Chair: Nour Moukalled (LB) & Mahmoud Aljurf (SA)**

14:00-14:20 New classifiers in follicular lymphoma: does it matter for treatment

Sandrine Roulland (FR)

14:20-14:30 From Indolent to Aggressive: Clinical Insights From A Case of Waldenström's Macroglobulinemia Transformed to High-Grade Lymphoma

Nour Moukalled (LB)

14:30-14:50 Discussion of the non-cellular therapy strategics including bispecifics

Charalampia Kyriakou (UK)

14:50-15:10 Discussion of the cellular therapy options: transplant, CART-T

Silvia Montoto (UK)

15:10-15:20 Discussion

**15:20-16:40 Session IV: Peripheral T cell lymphoma**

**Chair: Gandhi Damaj (FR) & Olivier Tournilhac (FR)**

15:20-15:40 New classifiers in TFH: does it matter for treatment

François Lemonnier (FR)

15:40-15:50 Refractory peripheral T cell lymphoma

Julieta Osorio Zuluaga (AE)

15:50-16:10 Standard treatment of the T-cell lymphoma with emphasis on allogeneic and autologous Transplantation + Q&A

Norbert Schmitz (DE)

16:10-16:30 The pipeline of T cell engaging therapy for T cell lymphoma: where do we stand? + Q&A

Pier Luigi Zinzani (IT)

16:30-16:40 Discussion

## Thursday, 6 November 2025 – continued

16:40-17:10 Coffee break

### 17:10-17:50 Session V: Cutaneous T cell lymphoma Chair: Norbert Schmitz (DE)

17:10-17:40 CTCL: State-of-the-art treatment and role of cellular therapy  
17:40-17:50 Discussion

Eva Domingo (ES)

## Friday, 7 November 2025

### 09:00-10:30 Session VI: Hodgkin lymphoma first line Chair: Anna Sureda (ES) & Alina Tanase (RO)

09:00-09:20 New classifiers in classical HL: does it matter for treatment  
09:20-09:30 Low-dose nivolumab combined with AVD chemotherapy in newly diagnosed advanced stage classic Hodgkin lymphoma  
09:30-09:50 State-of-the-art treatment of NLPHL and role of cellular therapy  
09:50-10:20 Choices and options in the first line  
10:20-10:30 Discussion

Cédric Rossi (FR)

Mobil Akhmedov (RU)  
Dennis Eichenauer (DE)  
Anna Sureda (ES)

10:30-11:00 Coffee break

### 11:00-12:20 Session VII: Hodgkin lymphoma in relapse and difficult to treat cases Chair: Ali Bazarbachi (LB) & Luca Castagna (IT)

11:00-11:10 Non-Myeloablative Allo-HSCT Using TLI After Failed Autologous Stem Cell Mobilization in Hodgkin Lymphoma  
11:10-11:40 Strategies at relapse  
11:40-11:50 Refractory Hodgkin Lymphoma with complex post-allo-HCT course and nivolumab-associated complications  
11:50-12:05 Lung Cancer Screening in Hodgkin Lymphoma  
12:05-12:20 Survivors - a UK national initiative  
12:20-12:30 Discussion  
12:20-13:20 Lunch break

Anisiia Luchkiv (UA)  
Ali Bazarbachi (LB)

Ludmila Federova (RU)

Kim Linton (UK)

### 13:20-14:40 Session VIII: Supportive care in cellular therapy Chairs: Anna Ossami Saidy (DE) & Rémy Duléry (US)

13:20-13:30 Severe Neurotoxicity and Spinal Myelopathy Following CD19 CAR-T Therapy in a Patient with Refractory DLBCL: A Case of Complex ICANS and Multidisciplinary Recovery  
13:30-13:50 Management of cytopenia after CART  
13:50-14:10 Neurological complications after CART  
14:10-14:30 From CRS to HLH following CART  
14:30-14:40 Discussion

Amjad Hmaid (UK)  
Martina Pennisi (IT)  
Roser Velasco (ES)  
Matteo Doglio (IT)

### 14:40-16:00 Session IX: Innovation in allotransplant Chair: Yasmina Serroukh (NL) & Olivier Hermine (FR)

14:40-15:00 Invariant NKT cells and risk of GVHD  
15:00-15:25 Artificial intelligence use in allo SCT  
15:25-15:45 Methodology and bias in registry studies  
15:45-16:00 Discussion

Olivier Hermine (FR)  
Simona Pagliuca (FR)  
Jacques-E. Galimard (FR)

### 16:00-16:10 Closing remarks

Ali Bazarbachi (LB) & Olivier Hermine (FR)

## THANKS TO OUR SPONSORS

Sponsored Lecture



LABORATOIRES

### Pierre Fabre

New ways to care

Silver Partner



Bronze Partner

